US2017348417A1PendingUtilityA1

Treatment of attention deficit disorders and associated symptoms

62
Assignee: PRICE RICHARD LOUISPriority: Apr 11, 2013Filed: Aug 22, 2017Published: Dec 7, 2017
Est. expiryApr 11, 2033(~6.7 yrs left)· nominal 20-yr term from priority
Inventors:Richard Louis Price
A61K 31/047A61K 45/06A61J 1/00A61K 9/0087A61K 2039/545A61K 39/395A61K 31/4168A61K 31/165A61K 31/155C07F 9/117A61K 9/0004A23L 3/3553A23B 2/775
62
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Disclosed is a single unit oral dosage form having, in combination, inositol and an extended release clonidine or extended release guanfacine. In one aspect, a method for treating ADHD and/or associated symptoms thereof includes administering to an ADHD patient the single unit oral dosage form. In another aspect, a method for treating ADHD and/or associated symptoms thereof includes administering to an ADHD patient inositol in combination with extended release clonidine or extended release guanfacine, whether administered separately or as a single dosage form.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A single unit oral dosage form comprising, in combination, inositol and an extended release clonidine or extended release guanfacine. 
     
     
         2 . The single unit oral dosage form of  claim 1 , wherein the inositol is present in an amount of from 6,000 mg to 32,400 mg. 
     
     
         3 . The single unit oral dosage form of  claim 1 , wherein the inositol is present in an amount of from 12,000 mg to 32,400 mg. 
     
     
         4 . The single unit oral dosage form of  claim 1 , wherein the inositol is present in an amount of from 15,000 mg to 22,000 mg. 
     
     
         5 . The single unit oral dosage form of  claim 1 , wherein the dosage form is provided as a comestible (medical food). 
     
     
         6 . A method of treating a patient having ADHD comprising administering to the patient the single unit oral dosage form of  claim 1 . 
     
     
         7 . The method of  claim 6 , wherein the single unit oral dosage form comprises guanfacine and wherein the inositol is present in an amount of from 6,000 mg to 32,400 mg. 
     
     
         8 . The method of  claim 7 , wherein the single unit oral dosage form is provided as a comestible (medical food). 
     
     
         9 . The method of  claim 7 , wherein at least a portion of the inositol is provided in an extended release form. 
     
     
         10 . The method of  claim 7 , wherein the inositol is present in an amount of from 12,000 mg to 32,400 mg and wherein the single unit oral dosage form is administered to the patient once per day. 
     
     
         11 . The method of  claim 10 , wherein at least a portion of the inositol is provided in an extended release form. 
     
     
         12 . The method of  claim 10 , wherein the single unit oral dosage form is provided as a comestible (medical food). 
     
     
         13 . The method of  claim 10 , wherein the guanfacine is present in an amount of from 1 mg to 7 mg. 
     
     
         14 . The method of  claim 13 , wherein the method treats one or more associated ADHD symptoms. 
     
     
         15 . The method of  claim 13 , wherein the single unit dosage form is provided as a comestible (medical food). 
     
     
         16 . The method of  claim 15 , wherein the inositol is present in an amount of from 15,000 mg to 22,000 mg. 
     
     
         17 . The method of  claim 16 , wherein at least a portion of the inositol is provided in an extended release form. 
     
     
         18 . The method of  claim 13 , wherein the method provides a laxative effect to the patient. 
     
     
         19 . The method of  claim 17 , wherein the single unit oral dosage form is administered to the patient once per day. 
     
     
         20 . The method of  claim 13 , wherein the method treats hyperfocus associated with ADHD in the patient.

Join the waitlist — get patent alerts

Track US2017348417A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.